These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33405314)

  • 1. Sex differences in factors predicting post-treatment opioid use.
    Davis JP; Eddie D; Prindle J; Dworkin ER; Christie NC; Saba S; DiGuiseppi GT; Clapp JD; Kelly JF
    Addiction; 2021 Aug; 116(8):2116-2126. PubMed ID: 33405314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
    O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
    Drug Alcohol Depend; 2020 Dec; 217():108261. PubMed ID: 32979735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
    Samples H; Williams AR; Olfson M; Crystal S
    J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health, Polysubstance Use, and Criminal Justice Involvement Among Adults With Varying Levels of Opioid Use.
    Winkelman TNA; Chang VW; Binswanger IA
    JAMA Netw Open; 2018 Jul; 1(3):e180558. PubMed ID: 30646016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for incarcerated adults with opioid use disorder in the United States: A systematic review with a focus on social determinants of health.
    Sugarman OK; Bachhuber MA; Wennerstrom A; Bruno T; Springgate BF
    PLoS One; 2020; 15(1):e0227968. PubMed ID: 31961908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying individual and environmental predictors of opioid and psychostimulant use among adolescents and young adults following outpatient treatment.
    Davis JP; Rao P; Dilkina B; Prindle J; Eddie D; Christie NC; DiGuiseppi G; Saba S; Ring C; Dennis M
    Drug Alcohol Depend; 2022 Apr; 233():109359. PubMed ID: 35219997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends and mental health correlates of nonmedical opioid use among criminal justice-involved African American men.
    Knighton JS; Stevens-Watkins D; Staton M; Pangburn K
    Addict Behav; 2018 Oct; 85():14-20. PubMed ID: 29803098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting opioid use disorder before and after the opioid prescribing peak in the United States: A machine learning tool using electronic healthcare records.
    Banks TJ; Nguyen TD; Uhlmann JK; Nair SS; Scherrer JF
    Health Informatics J; 2023; 29(2):14604582231168826. PubMed ID: 37042333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of depression on opioid withdrawal symptoms among smokers with opioid use disorder receiving medication-assisted opioid detoxification.
    Abarno CN; Chapman HM; Copeland AL
    Exp Clin Psychopharmacol; 2023 Apr; 31(2):370-377. PubMed ID: 36074624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in opioid use disorder and overdose among opioid-naive individuals receiving an opioid prescription in Massachusetts from 2011 to 2014.
    Burke LG; Zhou X; Boyle KL; Orav EJ; Bernson D; Hood ME; Land T; Bharel M; Frakt AB
    Addiction; 2020 Mar; 115(3):493-504. PubMed ID: 31691390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psycho-Social Correlates of Opioid Use Disorder among the US Adult Population: Evidence from the National Survey on Drug Use and Health, 2015-2018.
    Haider MR; Brown MJ; Gupta RD; Karim S; Olatosi B; Li X
    Subst Use Misuse; 2020; 55(12):2002-2010. PubMed ID: 32633664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid analgesic use and its sequelae: Opioid and other substance use disorders.
    Rhee TG; Rosenheck RA
    Early Interv Psychiatry; 2021 Aug; 15(4):975-982. PubMed ID: 32930517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study.
    Hudgins JD; Porter JJ; Monuteaux MC; Bourgeois FT
    PLoS Med; 2019 Nov; 16(11):e1002922. PubMed ID: 31689290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management.
    Pergolizzi JV; Raffa RB; Rosenblatt MH
    J Clin Pharm Ther; 2020 Oct; 45(5):892-903. PubMed ID: 31986228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events among adult Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
    O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
    Drug Alcohol Depend; 2021 Apr; 221():108555. PubMed ID: 33596496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing interagency collaboration to address the opioid epidemic: A scoping review of joint criminal justice and healthcare initiatives.
    Yatsco AJ; Champagne-Langabeer T; Holder TF; Stotts AL; Langabeer JR
    Int J Drug Policy; 2020 Sep; 83():102849. PubMed ID: 32653668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of anxiety sensitivity on opioid use disorder treatment outcomes.
    Baxley C; Weinstock J; Lustman PJ; Garner AA
    Exp Clin Psychopharmacol; 2019 Feb; 27(1):64-77. PubMed ID: 30080059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.